ICD-10-CM Billable Code

C50.21

Malignant neoplasm of upper-inner quadrant of breast, female

Clinical Classification Guidelines

Medical Intelligence & Overview

ICD-10 code C50.21 refers to malignant tumors located specifically in the upper-inner quadrant of the female breast. This area is one of the common sites for breast cancer, representing a significant concern for women's health. Recognizing the characteristics and understanding the diagnosis and treatment options can help in managing this condition effectively.

Causes & Symptoms

Clinical Causes: Genetic mutations, especially involving BRCA1 and BRCA2 genes Family history of breast cancer Hormonal factors, including prolonged exposure to estrogen Age, with higher risk as women grow older Radiation exposure to the chest area Lifestyle factors such as alcohol consumption, obesity, and lack of physical activity Previous benign breast diseases or biopsies

Key Symptoms: Lump or mass in the upper-inner quadrant of the breast Changes in the size or shape of the breast Skin changes over the affected area, such as dimpling or puckering Nipple alterations, including inversion or discharge Persistent pain in the affected region Swelling or redness in the breast

Diagnostic & Treatment

Diagnosis Path: Diagnosing cancer in the upper-inner quadrant of the breast typically involves a combination of methods: - Physical exams to detect any lumps or abnormalities - Imaging tests such as mammography, ultrasound, or MRI to visualize the suspicious areas - Biopsies, including fine-needle aspiration or core needle biopsy, to obtain tissue samples for histopathological analysis - Additional tests like genetic counseling or molecular profiling may be recommended for understanding the tumor's characteristics

Treatment Protocols: Treatment strategies are tailored to the individual, considering the tumor’s size, stage, and overall health. Common approaches include: - Surgery, such as lumpectomy or mastectomy, to remove the tumor and surrounding tissue - Radiation therapy to destroy residual cancer cells post-surgery - Chemotherapy, either before or after surgery, to address systemic disease - Hormonal therapy, especially if the tumor is hormone receptor-positive - Targeted therapies that focus on specific molecules involved in tumor growth - Follow-up care for monitoring and managing any recurrence or side effects

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is C50.21 a billable ICD-10 code?
Yes, C50.21 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report C50.21?
Clinical documentation must specify the nature of Malignant neoplasm of upper-inner quadrant of breast, female and any associated comorbidities for accurate reporting.

Cite this Clinical Reference